INKT MiNK Therapeutics, Inc.
$10.63▲ +1.92%
Healthcare
Other
Volume 10.1K
Avg Volume (10D) 13.1K
Key Metrics & Fundamentals
Market Cap
$54.24M
P/E Ratio
–
Div Yield
0.00%
52W Range
8.48 - 16.93
% vs 50 MA
-6.78%
% vs 200 MA
-5.99%
RSI-14
47.3
MACD Histogram
+0.0300
Beta (1Y vs SPY)
0.66
Free Cash Flow
-$2.08M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.18M
COGS
–
Operating Exp
$3.22M
Operating Income
-$3.22M
EBIT
-$3.22M
Pretax Income
-$3.13M
Net Income
-$3.13M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
GlobeNewswire · Oct 2, 2026 9:00 AM ET
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
GlobeNewswire · Sep 30, 2026 7:57 AM ET
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 11:28 PM ET
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 8:46 PM ET
MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...
GuruFocus.com · Aug 13, 2026 7:07 PM ET
MiNK Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 13, 2026 12:04 PM ET
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
GlobeNewswire · Aug 13, 2026 7:30 AM ET
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
GlobeNewswire · Aug 6, 2026 12:00 PM ET
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
GlobeNewswire · Aug 6, 2026 8:19 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See INKT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.